DFTX is trading 17% up at $42.19 as investors react to positive Phase 3 results for its depression drug candidate and a significant capital raise.
- The stock is extending gains following topline results from the Emerge trial in major depressive disorder, which met its primary endpoints.
- Definium secured a $700 million equity offering, bolstering its balance sheet for late-stage pipeline development and commercialization plans.
- Multiple analyst upgrades have followed the clinical data, reinforcing market confidence in the commercial potential of the DT120 candidate.